Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.
Established products fueled at 12% jump in first-quarter sales.
The app for the smartwatch includes secure encrypted messaging.
The company's first-ever road show has stimulated sales for its new ClinicalKey reference tool, grabbing the attention of time-harried doctors for as long as 30 minutes during the workday.
New online and print DTC advertising targeting US patients with lupus will appear "within weeks," said executives from Human Genome Sciences. Can the campaign revive blockbuster fortunes for Benlysta?
Roche will help promote Merck's newly approved hepatitis C drug Victrelis (boceprevir) under a strategic partnership that may help bolster the firms' chances in an upcoming market share battle. The agreement stunned Wall Street, since Merck and Roche already sell rival versions of a standard hepatitis C treatment.
Vertex said it stands ready to market hepatitis C drug telaprevir, under the brand name Incivek, and its approval could come as early as this month.
When co-marketers Human Genome Sciences and GlaxoSmithKline launch newly approved lupus drug Benlysta later this month, reps will be able to tout a broad label.
Savient Pharmaceuticals launched Krystexxa (pegloticase), an orphan drug for chronic gout, on Monday, and deployed a mix of sales reps, education specialists and business managers to help expedite reimbursement from payers, executives said on a conference call.
Amgen received FDA approval for a higher dose of its denosumab injection, Xgeva, which puts the drug in competition with Novartis' Zometa (zoledronic acid) for the prevention of bone damage in patients with certain types of cancer. A lower dose of denosumab, Prolia, was approved by FDA in June for osteoporosis.
Ferring Pharmaceuticals is launching its first branded TV ad with spots for its Lysteda treatment for heavy menstrual bleeding. The company had to soothe some network execs who at first balked at the ad's blunt talk of the condition.
AstraZeneca has launched a professional site for its Vimovo arthritis drug that features a live chat option.
As the number of FDA-approved fibromyalgia therapies has grown, so has patient hope. However, the condition is still not well understood by the medical community overall, hampering uptake of branded drugs approved for the disorder.
GlaxoSmithKline's FDA approval for Cervarix, received last week as rival Merck expanded its Gardasil label, heralds a market-share battle that may hinge on science.
Schering-Plough announced FDA approval on a key pipeline antipsychotic today, and is developing marketing materials and building a US sales force for the Q4 launch.
California-based Zogenix announced a partnership with Astellas to co-promote Sumavel DosePro, a subcutaneous injection for migraine relief.
Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.